Clinical Trial Update: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

This entry reports that a Phase 1/2 study evaluating GC012F injection for refractory systemic lupus erythematosus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GC012F

Snippet

Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. | Conditions: Refractory Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: RECRUITING